Dachaigh › Galar Crohn › Louisiana
Sgrùdaidhean clionaigeach Galar Crohn ann an Louisiana
Tha 11 sgrùdaidhean airson Galar Crohn a’ lorg phàirtichean aig làraichean ann an Louisiana.
Bailtean ann an Louisiana
- Lafayette7 sgrùdaidhean
- Metairie5 sgrùdaidhean
- Shreveport3 sgrùdaidhean
- Baton Rouge3 sgrùdaidhean
- Monroe3 sgrùdaidhean
- New Orleans3 sgrùdaidhean
Teacsa sgrùdaidh oifigeil (Beurla)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Group and Endocenter: Mandeville, la /ID# 284186, Mandeville
- Metropolitan Gastroenterology Associates - Metairie /ID# 283922, Metairie
- Willis-Knighton Medical Center /ID# 280572, Shreveport
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Baton Rouge General Medical Center - Bluebonnet Campus, Baton Rouge
- Combined Gastro LLC, Lafayette
- GI Alliance, Metairie
A’ fastadhÌre 4
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT06581328A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
- Delta Research Partners, LLC, West Monroe
A’ fastadhÌre 2/3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Care Access - New Iberia, New Iberia
- Louisiana Research Center, Shreveport
A’ fastadhÌre 3
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Tandem Intermediate, LLC - Houma-Site Number: 8400034, Houma
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- agus 4 a bharrachd
A’ fastadhÌre 3
Aoisean 16 gu 80 · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- GI Alliance - Metairie-Site Number: 8400124, Metairie
- agus 1 a bharrachd
A’ fastadhÌre 3
Aoisean 16 gu 80 · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Tandem Clinical Research, Houma
A’ fastadhÌre 2
Aoisean 18 gu 85 · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06226883A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- GI Alliance, Metairie
- Tulane University, New Orleans
A’ fastadhÌre 4
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT07577843A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Lafayette
- Mirador Therapeutics Selected Site, Marrero
- Mirador Therapeutics Selected Site, Shreveport
A’ fastadhÌre 2
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 12 Màrt 2026 · NCT07113522Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.